BS_A1VEGWTR
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 55.78186596583443
- age_years
- 15.901
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.345
- BILE_ACID_METABOLISM+0.278
- NOTCH_SIGNALING+0.244
- FATTY_ACID_METABOLISM+0.181
- ANDROGEN_RESPONSE+0.173
- ADIPOGENESIS+0.166
- PROTEIN_SECRETION+0.157
- KRAS_SIGNALING_DN+0.138
- P53_PATHWAY+0.132
- HEME_METABOLISM+0.118
Top 10 suppressed
- E2F_TARGETS-0.538
- G2M_CHECKPOINT-0.479
- MYC_TARGETS_V1-0.446
- ANGIOGENESIS-0.394
- MYC_TARGETS_V2-0.385
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.377
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.376
- DNA_REPAIR-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.299
- PANCREAS_BETA_CELLS-0.297
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PEP9NZXN | low-grade glioma | — | 0.931 |
| 2 | BS_55P8HPYD | pilocytic astrocytoma | — | 0.837 |
| 3 | C3L-00893 | — | cohortA1 | 0.834 |
| 4 | C3L-02958 | — | cohortA1 | 0.798 |
| 5 | BS_66ABA973 | pilocytic astrocytoma | — | 0.797 |
| 6 | BS_JKXA3FQC | low-grade glioma | — | 0.780 |
| 7 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.779 |
| 8 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.778 |
| 9 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.778 |
| 10 | BS_TMTV769C | low-grade glioma | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.345 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.278 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.244 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.181 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.173 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.166 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.157 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.138 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.132 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.118 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.114 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.095 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.073 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.067 | Inavolisib | — uncovered |
| PEROXISOME | 0.062 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.059 | Inavolisib | — uncovered |
| MYOGENESIS | 0.032 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.015 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.013 | Inavolisib | — uncovered |